Pfizer Covid-19 Booster Accelerates Immune Response in Children 5 to 11 Years Old

Share Us

610
Pfizer Covid-19 Booster Accelerates Immune Response in Children 5 to 11 Years Old
15 Apr 2022
min read

News Synopsis

A booster dose of  Pfizer and BioNTech SE's Covid-19 vaccine generated a strong immune response in children ages 5 to 11. The two companies said a recent study of booster shots found that booster injections significantly increased antibody levels against the Omicron variant. The shot also increased the supply of antibodies against the original strain in which the vaccine was designed to fight.

According to a Pfizer spokesperson, the company had not yet determined the effectiveness of the booster at the age of 5-11 years. Not enough illnesses have been made to make such a decision, but researchers may learn more as the process progresses.

Pfizer and BioNTech are studying vaccines in children under the age of five, even after discovering that the first two-dose series did not work well for the Omicron variant. Researchers are studying the third dose, and Pfizer says results may come out this month.

In October, the FDA approved the use of the Pfizer BioNTech vaccine in children aged 5 to 11 years after researchers discovered that it was 90.7% effective in preventing symptomatic Covid-19.

TWN In-Focus